Patents Examined by Jennifer A Benavides
  • Bispecific binding agents binding to CLDN18.2 and CD3
    Patent number: 11739145
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: August 29, 2023
    Inventors: Matthew Bernett, Alex Nisthal, Gregory Moore
  • Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same
    Patent number: 11685784
    Abstract: The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: June 27, 2023
    Assignee: CHINA MEDICAL UNIVERSITY HOSPITAL
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen
  • Anti-transferrin receptor antibody and uses thereof
    Patent number: 11672872
    Abstract: Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: June 13, 2023
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim